Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 10/20 | 0.53 |
| ▸ | ELANE | P08246 | 3/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | BUB1 | O43683 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6068569 | 0.92 | ELANE (0.52) | PDE5AELANEADORA3KCNH2ATM | |
| SCHEMBL6068675 | 0.87 | PTGDR2 (0.53) | ELANEALDH1A1GAAMAPT | |
| SCHEMBL175370 | 0.85 | ATM (0.53) | PDE5AADORA3KCNH2ATMMAPT | |
| SCHEMBL175229 | 0.85 | PDE5A (0.47) | PDE5AELANEBUB1MEN1KMT2A | |
| SCHEMBL1217408 | 0.84 | L3MBTL1 (0.61) | ELANEMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL174160 | 0.84 | ATM (0.54) | PDE5AADORA3KCNH2ATMMEN1 | |
| SCHEMBL19144727 | 0.83 | PDE5A (0.46) | PDE5AADORA3KCNH2ATMBUB1 | |
| SCHEMBL3953305 | 0.83 | PDE5A (0.54) | PDE5AADORA3KCNH2ATM | |
| SCHEMBL4929205 | 0.83 | ATM (0.53) | PDE5AADORA3KCNH2ATMMAPT | |
| SCHEMBL4937101 | 0.83 | ATM (0.53) | PDE5AADORA3KCNH2ATMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017025981-A1 | PROCESS FOR THE PREPARATION OF METHYL 4,6-DIAMINO-2-[L-(2-FHIOROBENZVR)-LH-PYRAZOLO I3,4-BLPVRIDIN-3-VN-5-PYRIMIDINYL(METHVL)CARBAMATE AND ITS POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2017-02-16 | — | — | WO | claimed |
| US-12435080-B2 | sGC stimulators | TISENTO THERAPEUTICS INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20220017515-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2022-01-20 | — | — | US | disclosed |
| US-20220017515-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2022-01-20 | — | — | US | disclosed |
| US-11180493-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11180493-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3421470-B1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES IN CRYSTALLINE FORM | ADVERIO PHARMA GMBH (DE) | 2021-01-20 | — | — | EP | disclosed |
| US-10633356-B2 | Hydrates of substituted 5-fluoro-1H-pyrazolopyridines | ADVERIO PHARMA GMBH (DE) | 2020-04-28 | — | — | US | disclosed |
| US-10633357-B2 | Intermediates and process for preparing intermediates in the production of substituted pyrazolopyridines | ADVERIO PHARMA GMBH (DE) | 2020-04-28 | — | — | US | disclosed |
| US-20200071318-A1 | SGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2020-03-05 | — | — | US | disclosed |
| US-6903089-B1 | Lactam-substituted pyrazolopyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-06-07 | — | — | US | disclosed |
| US-6833364-B1 | Inhibiting degradation of cyclic guanosine monophosphate; cardiovascular disorders; such as 3-(4-amino-5-cyclopropyl-pyrimidin-2-yl)-1-(2-fluorobenzyl)1H-pyrazolo-(3,4 -b)-pyridine | BAYER HEALTHCARE AG (DE) | 2004-12-21 | — | — | US | disclosed |
| US-20040235863-A1 | Morpholine-bridged pyrazolopyridine derivatives | BAYER HEALTHCARE AG (DE) | 2004-11-25 | — | — | US | disclosed |
| US-20040224945-A1 | Novel substituted pyrazole derivatives | BAYER HEALTHCARE AG (DE) | 2004-11-11 | — | — | US | disclosed |
| US-20040171832-A1 | Novel sulfonate substituted pyrazol pyridine derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-09-02 | — | — | US | disclosed |
| US-6743798-B1 | CARDIOVASCULAR DISORDERS; VASORELAXATION, INHIBITION OF PLATELET AGGREGATION, DECREASE IN BLOOD PRESSURE; STIMULATION OF SOLUBLE GUANYLATE CYCLASE AND AN INTRACELLULAR CGMP INCREASE | BAYER AKTIENGESELLSCHAFT (DE) | 2004-06-01 | — | — | US | disclosed |
| US-20040082596-A1 | Novel carbamate-substituted pyrazolopyridine derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-04-29 | — | — | US | disclosed |
| US-20040067937-A1 | Novel sulfonamide-substituted pyrazolopyridine derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-04-08 | — | — | US | disclosed |
| US-6693102-B2 | CARDIOVASCULAR DISORDERS; HYPOTENSIVE AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2004-02-17 | — | — | US | disclosed |
| US-20020173514-A1 | Pyridine-substituted pyrazolopyridine derivatives | BAYER HEALTHCARE AG (DE) | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071318-A1 | SGC STIMULATORS | GUCY1A2, GMPS, PDE2A | PDE5A 12/4885ELANE 2411/4885ADORA3 1006/4885 |
| US-20040224945-A1 | Novel substituted pyrazole derivatives | CYP11B2, CYP11B1, ADRB3 | PDE5A 506/4885ELANE 2735/4885ADORA3 260/4885 |
| US-20220017515-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, PDE2A | PDE5A 12/4885ELANE 2419/4885ADORA3 1072/4885 |
| US-10633356-B2 | Hydrates of substituted 5-fluoro-1H-pyrazolopyridines | CYP3A5, KCNK5, CYP2F1 | PDE5A 72/4885ELANE 3905/4885ADORA3 1868/4885 |
| US-12435080-B2 | sGC stimulators | GUCY1A2, PRKG1, PDE2A | PDE5A 12/4885ELANE 2419/4885ADORA3 1072/4885 |
| US-20020173514-A1 | Pyridine-substituted pyrazolopyridine derivatives | GUCY1A1, GUCY1A2, GUCY1B1 | PDE5A 6/4885ELANE 2833/4885ADORA3 448/4885 |
| US-20040082596-A1 | Novel carbamate-substituted pyrazolopyridine derivatives | GPR3, NOS3, NPR3 | PDE5A 28/4885ELANE 4271/4885ADORA3 160/4885 |
| US-10633357-B2 | Intermediates and process for preparing intermediates in the production of substituted pyrazolopyridines | CYP3A5, CYP4F2, CYP2F1 | PDE5A 109/4885ELANE 4703/4885ADORA3 2133/4885 |
| US-11180493-B2 | SGC stimulators | GUCY1A2, GMPS, PDE2A | PDE5A 12/4885ELANE 2411/4885ADORA3 1006/4885 |
| US-20040171832-A1 | Novel sulfonate substituted pyrazol pyridine derivatives | NOS3, PDE3A, GPR3 | PDE5A 12/4885ELANE 4219/4885ADORA3 112/4885 |
| US-20040067937-A1 | Novel sulfonamide-substituted pyrazolopyridine derivatives | GUCY1A2, GUCY1A1, GUCY1B2 | PDE5A 7/4885ELANE 3493/4885ADORA3 318/4885 |
| US-20040235863-A1 | Morpholine-bridged pyrazolopyridine derivatives | GUCY1A1, PDE1A, PDE3B | PDE5A 5/4885ELANE 3522/4885ADORA3 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.